Concerns rise among Korean drug makers

Published: 2007-09-03 07:00:00

Updated: 2007-09-03 07:00:00

The domestic pharmaceutical sector is expected to face an inevitable blow following the Korean government's plan to deny a local pharmaceutical company the license to sell generic drugs for at least 12 months, if the U.S. company that produced the original drug file a lawsuit over patent infringe...

Fees

- Email service daily and homepage access.

$300 per month. ($3,240 per year)
5 Email holders per each company.
Anual contract base.

Latest News

Which are outstanding tetravalent vaccines even for the young?

Disease treated the most with clinical trial drugs is respiratory disorder like lung cancer

Who will be the next Pharmaceutical Safety Bureau Director?

Celltrion completes clinical trials for Remsima SC for European approval

Sales listed pharmas made in the first half of the year

TOP

BACK